JWH-045

JWH-045_structure.png Chemical structure of JWH-045

JWH-045 is a synthetic cannabinoid that acts as a potent agonist at the cannabinoid receptors. It is part of the naphthoylindole family of compounds, which were originally developed for research purposes to study the endocannabinoid system.

Chemical Structure and Properties

JWH-045 is chemically classified as a naphthoylindole, with the IUPAC name (2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone. The compound has a molecular formula of C₂₃H₂₃NO and a molecular weight of 329.43 g/mol. The structure consists of a naphthalene group attached to a methanone bridge, which is further connected to a substituted indole group.

Pharmacology

JWH-045 functions as a full agonist at both the CB₁ and CB₂ cannabinoid receptors. These receptors are part of the G protein-coupled receptor family and are primarily involved in the modulation of neurotransmitter release in the central nervous system and immune system, respectively.

Receptor Affinity

JWH-045 has been shown to have a higher affinity for the CB₂ receptor compared to the CB₁ receptor, which suggests potential applications in modulating immune responses without significant psychoactive effects. However, detailed studies on its selectivity and efficacy are limited.

Potential Applications

While JWH-045 was initially synthesized for research purposes, its potential applications could include:

• Investigating the role of CB₂ receptors in immune modulation.
• Exploring therapeutic avenues for conditions such as inflammation, pain management, and autoimmune disorders.

Legal Status

The legal status of JWH-045 varies by country. In many jurisdictions, it is classified as a controlled substance due to its structural similarity to other synthetic cannabinoids that have been associated with recreational use and potential health risks.

Safety and Toxicology

There is limited data on the safety and toxicological profile of JWH-045. As with other synthetic cannabinoids, there is a potential for adverse effects, including tachycardia, anxiety, and hallucinations. Long-term effects and the potential for dependency are not well understood.

Research and Development

JWH-045 continues to be of interest in the field of cannabinoid research, particularly for its potential to selectively target CB₂ receptors. Ongoing studies aim to elucidate its pharmacokinetics, receptor binding dynamics, and therapeutic potential.

Also see

• Synthetic cannabinoids
• Cannabinoid receptor
• Endocannabinoid system
• JWH-018
• CB1 receptor
• CB2 receptor